Product Images Terazosin Hydrochloride

This is a summary of the results of Study 1, with Figure 1 showing the mean change in Total Symptom Score from baseline and mean increase in Peak Flow Rate (mLsec) from baseline. The study evaluated the effectiveness of Terazosin and included a month-long treatment phase. The baseline values can be found in the table above. The asterisk indicates a statistically significant difference with a p-value less than 0.05 when compared to the placebo group.*

This is a figure of a long-term, open-label, non-placebo controlled study that shows the mean change in total symptom score from baseline over a period of 30 months. The study involved 494 participants and the graph shows a decrease in symptom score over time, with a statistically significant improvement from baseline after 7 months. The baseline mean symptom score was 10.7.*

The figure represents the mean change in peak flow rate from baseline in a long-term open-label study. The study was not placebo-controlled and the sample size is not available. The mean change from baseline at different months is shown on the graph with a statistical significance level indicated by +p<005 vs. baseline. The baseline mean was 99.*

This is a description of a drug called Terazosin HCl Peel. It comes in the form of capsules containing 2mg of Terazosin HCl each. The product is manufactured by Cadista Pharmaceuticals, Inc. and packaged by Physician Partner. The capsules are ivory opaque cap and body printed with "TL 384" in black ink. The product ID is PT081290, and it is available by prescription only. This drug should be stored at controlled room temperature. There is a cautionary instruction to keep the medication out of reach of children.*